Aprea Therapeutics
APRE
22 hedge funds and large institutions have $1.45M invested in Aprea Therapeutics in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 6 closing their positions.
3.55% less ownership
Funds ownership: 27.79% → 24.24% (-3.5%)
4% less funds holding
Funds holding: 23 → 22 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
39% less capital invested
Capital invested by funds: $2.39M → $1.45M (-$941K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$418K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
+$148K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$62.7K |
| 4 |
Jane Street
New York
|
+$57.2K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$29.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$207K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$202K |
| 3 |
SCM
Sio Capital Management
New York
|
-$166K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$123K |
| 5 |
HF
HRT Financial
New York
|
-$18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LCM
26
Landscape Capital Management
Englewood,
New Jersey
| – | -$15.5K | -10,496 | Closed |
|
|
MLA
27
MB, Levis & Associates
Center Valley,
Pennsylvania
| – | -$1.19K | -806 | Closed |
|
28
Citigroup
New York
| – | -$7 | -5 | Closed |
|
APRE Hedge Fund Activity: Q4 2025 in Review
22 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q4 2025, worth a combined $1.45M — down 39% from $2.39M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of APRE and 5 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 5 added.
The largest buyer was Murchinson, opening a new position worth an estimated $418K. The largest seller was AIGH Capital Management, cutting an estimated $207K.
- 22 institutional investors held Aprea Therapeutics (APRE) as of Q4 2025, down from 23 in Q3 2025.
- Funds reported $1.45M of Aprea Therapeutics stock for Q4 2025, down 39% quarter-over-quarter.
- 5 funds opened new Aprea Therapeutics positions in Q4 2025 and 6 closed out, a net change of -1 holder.
- The largest Aprea Therapeutics buyer in Q4 2025 was Murchinson, an estimated $418K added.
- The largest Aprea Therapeutics seller in Q4 2025 was AIGH Capital Management, an estimated $207K sold.
Based on aggregated 13F filings for Q4 2025.